Biocon Intrinsic Value
Biocon (BIOCON) median intrinsic value is ₹179.18 from 9 valuation models (range ₹128–₹903), vs current price ₹426.35 — -58.0% downside (Trading Above Calculated Value), margin of safety -100.0%. Analyse BIOCON FII DII holdings to track promoter, FII and institutional holdings.
BIOCON Valuation Methods Summary — DCF, Graham Number & P/E
Biocon intrinsic value across 9 models vs current price ₹426.35 — upside/downside and value range per method. For current market price and key ratios, visit BIOCON share price.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹127.91 | ₹102.33 - ₹153.49 | -70.0% | EPS: ₹3.16, Sector P/E: 22x |
| Book Value Method | asset | ₹903.13 | ₹812.82 - ₹993.44 | +111.8% | Book Value/Share: ₹451.57, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹447.55 | ₹402.80 - ₹492.31 | +5.0% | Revenue/Share: ₹223.77, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹473.49 | ₹426.14 - ₹520.84 | +11.1% | EBITDA: ₹3840.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹322.83 | ₹258.26 - ₹387.40 | -24.3% | CF Growth: 14.1%, Discount: 15% |
| PEG Ratio Method | growth | ₹127.91 | ₹115.12 - ₹140.70 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹127.91 | ₹115.12 - ₹140.70 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| Graham Defensive Method | conservative | ₹179.18 | ₹161.26 - ₹197.10 | -58.0% | EPS: ₹3.16, BVPS: ₹451.57 |
| Dividend Yield Method | dividend | ₹127.91 | ₹115.12 - ₹140.70 | -70.0% | DPS: ₹0.50, Target Yield: 2.5% |
BIOCON Intrinsic Value vs Market Price — All Valuation Models
Biocon fair value range ₹128–₹903 vs current market price ₹426.35 across 9 valuation models. Read BIOCON dividend payout details for the complete payout history and dividend yield track record.
BIOCON Intrinsic Value Analysis — Undervalued or Overvalued?
Biocon median intrinsic value ₹179.18, current price ₹426.35 — Trading Above Calculated Value by 58.0%, margin of safety -100.0%.
What is the intrinsic value of BIOCON?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Biocon (BIOCON) is ₹179.18 (median value). With the current market price of ₹426.35, this represents a -58.0% variance from our estimated fair value.
The valuation range spans from ₹127.91 to ₹903.13, indicating ₹127.91 - ₹903.13.
Is BIOCON undervalued or overvalued?
Based on our multi-method analysis, Biocon (BIOCON) appears to be trading above calculated value by approximately 58.0%.
BIOCON Financial Health — Key Ratios vs Industry Benchmarks
Biocon financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 1.33 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 2.2% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 20.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.29x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
BIOCON Cash Flow Quality — Operating & Free Cash Flow
Biocon operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹1,994 Cr | ₹1,053 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹4,061 Cr | ₹3,960 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹2,954 Cr | ₹2,453 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹1,853 Cr | ₹-5,277 Cr | Positive Operating Cash Flow | 6/10 |
| March 2022 | ₹1,177 Cr | ₹346 Cr | Positive Free Cash Flow | 7/10 |